One-Time brain infusion aims to tame Huntington's

NCT ID NCT06826612

Recruiting now Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a new gene therapy called SPK-10001 for people with Huntington's disease. It involves a one-time infusion into specific areas of the brain. The main goal is to see if it is safe and if it can slow down the worsening of movement and daily function. About 53 adults will take part in this early-phase trial.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HUNTINGTON DISEASE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

choreatic disease Huntington disease movement disorder Rare Diseases

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HUNTINGTON DISEASE

Contacts and locations

Locations

Beth Israel Deaconess Medical Center
RECRUITING

Boston, Massachusetts, 02215, United States
Ohio State University
RECRUITING

Columbus, Ohio, 43221, United States
University of Cincinnati/Cincinnati Children's Hospital
RECRUITING

Cincinnati, Ohio, 45221, United States
University of Pennsylvania
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
University of Pittsburg
RECRUITING

Pittsburgh, Pennsylvania, 15213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.